GSK’s RSV Vaccine, Arexvy, Accepted for Review by Health Canada for Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
Submission supported by positive results of a Phase III study showing immune response and tolerability in adults aged 50-59 Adults aged 50 and above with underlying medical conditions are at… Read More




